Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model
Migraine is a complex brain disorder, and understanding the complexity of this prevalent disease could improve quality of life for millions of people. Familial Hemiplegic Migraine type 2 (FHM2) is a subtype of migraine with aura and co-morbidities like epilepsy/seizures, cognitive impairments and ps...
Saved in:
Published in | Scientific reports Vol. 6; no. 1; p. 22047 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
25.02.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Migraine is a complex brain disorder, and understanding the complexity of this prevalent disease could improve quality of life for millions of people. Familial Hemiplegic Migraine type 2 (FHM2) is a subtype of migraine with aura and co-morbidities like epilepsy/seizures, cognitive impairments and psychiatric manifestations, such as obsessive-compulsive disorder (OCD). FHM2 disease-mutations locate to the
ATP1A2
gene encoding the astrocyte-located α
2
-isoform of the sodium-potassium pump (α
2
Na
+
/K
+
-ATPase). We show that knock-in mice heterozygous for the FHM2-associated G301R-mutation (α
2
+/G301R
) phenocopy several FHM2-relevant disease traits e.g., by mimicking mood depression and OCD.
In vitro
studies showed impaired glutamate uptake in hippocampal mixed astrocyte-neuron cultures from α
2
G301R/G301R
E17 embryonic mice, and moreover, induction of cortical spreading depression (CSD) resulted in reduced recovery in α
2
+/G301R
male mice. Moreover, NMDA-type glutamate receptor antagonists or progestin-only treatment reverted specific α
2
+/G301R
behavioral phenotypes. Our findings demonstrate that studies of an
in vivo
relevant FHM2 disease knock-in mouse model provide a link between the female sex hormone cycle and the glutamate system and a link to co-morbid psychiatric manifestations of FHM2. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep22047 |